SITAVIG Drug Patent Profile
✉ Email this page to a colleague
When do Sitavig patents expire, and when can generic versions of Sitavig launch?
Sitavig is a drug marketed by Epi Hlth and is included in one NDA. There are three patents protecting this drug.
This drug has forty-six patent family members in twenty-nine countries.
The generic ingredient in SITAVIG is acyclovir. There are fifty-six drug master file entries for this compound. Sixty-two suppliers are listed for this compound. Additional details are available on the acyclovir profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sitavig
A generic version of SITAVIG was approved as acyclovir by TEVA on April 22nd, 1997.
Summary for SITAVIG
| International Patents: | 46 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 168 |
| Clinical Trials: | 1 |
| Patent Applications: | 4,058 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for SITAVIG |
| What excipients (inactive ingredients) are in SITAVIG? | SITAVIG excipients list |
| DailyMed Link: | SITAVIG at DailyMed |
Recent Clinical Trials for SITAVIG
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Bayer | Phase 3 |
US Patents and Regulatory Information for SITAVIG
SITAVIG is protected by three US patents.
Patents protecting SITAVIG
Mucoadhesive buccal tablets for the treatment of orofacial herpes
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HERPES LABIALIS
Mucosal bioadhesive slow release carrier for delivering active principles
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HERPES LABIALIS
Mucosal bioadhesive slow release carrier for delivering active principles
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HERPES LABIALIS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Epi Hlth | SITAVIG | acyclovir | TABLET;BUCCAL | 203791-001 | Apr 12, 2013 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
| Epi Hlth | SITAVIG | acyclovir | TABLET;BUCCAL | 203791-001 | Apr 12, 2013 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
| Epi Hlth | SITAVIG | acyclovir | TABLET;BUCCAL | 203791-001 | Apr 12, 2013 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SITAVIG
See the table below for patents covering SITAVIG around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Russian Federation | 2008139869 | БИОАДГЕЗИВНЫЙ НОСИТЕЛЬ С ЗАМЕДЛЕННЫМ ВЫСВОБОЖДЕНИЕМ ДЛЯ СЛИЗИСТЫХ ОБОЛОЧЕК, ПРЕДНАЗНАЧЕННЫХ ДЛЯ ДОСТАВКИ АКТИВНЫХ КОМПОНЕНТОВ | See Plans and Pricing |
| Argentina | 060085 | VEHICULO BIOADHESIVO DE LIBERACION LENTA EN MUCOSAS PARA ADMINISTRAR PRINCIPIOS ACTIVOS | See Plans and Pricing |
| Serbia | 57430 | MUKOADHEZIVNE BUKALNE TABLETE ZA LEČENJE OROFACIJALNOG HERPESA (MUCOADHESIVE BUCCAL TABLETS FOR THE TREATMENT OF OROFACIAL HERPES) | See Plans and Pricing |
| Japan | 5242548 | See Plans and Pricing | |
| Cyprus | 1109723 | See Plans and Pricing | |
| Canada | 2647123 | VECTEUR MUQUEUX BIOADHESIF A LIBERATION LENTE POUR LA DELIVRANCE DE PRINCIPES ACTIFS (MUCOSAL BIOADHESIVE SLOW RELEASE CARRIER FOR DELIVERING ACTIVE PRINCIPLES) | See Plans and Pricing |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SITAVIG
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0809498 | SPC/GB10/012 | United Kingdom | See Plans and Pricing | PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112 |
| 0809498 | 10C0038 | France | See Plans and Pricing | PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2022 - 2023
NCE-1 Patent Challenge Dates 2022 - 2023
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2022, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
